Novo Nordisk shares are trading lower following a report showing most patients using weight loss drugs like Wegovy stop within a year.
Portfolio Pulse from Benzinga Newsdesk
Novo Nordisk's shares are trading lower following a report that most patients using weight loss drugs like Wegovy stop within a year.
July 11, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novo Nordisk's shares are trading lower due to a report indicating high discontinuation rates for its weight loss drug, Wegovy.
The report suggests that most patients stop using Wegovy within a year, which could potentially lead to lower sales for Novo Nordisk. This negative news is likely to impact investor sentiment and could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100